Results 251 to 260 of about 53,193 (289)

Case Report: Efficacy of anlotinib and sintilimab in treating lung adenocarcinoma with RET fusion and PD-L1 expression. [PDF]

Front Pharmacol
Bao H, Zhang J, Wang Y, Chen Z, Luo X, Li T, Su H, Bao H, Cao X, Lin L.   +9 more
europepmc   +1 more source

A case of neoadjuvant targeted therapy with pralsetinib for locally advanced lung adenocarcinoma with RET fusion mutation. [PDF]

J Cardiothorac Surg
Chunmao W, Haijie C, Zitong W, Zhi Y.
europepmc   +1 more source

RET Fusion Testing in Patients With NSCLC

RET inhibitors with impressive overall response rates are now available for patients with NSCLC, yet the identification of RET fusions remains a difficult challenge. Most guidelines encourage the upfront use of next-generation sequencing (NGS), or alternatively, fluorescence in situ hybridization (FISH) or reverse transcriptase-polymerase chain ...
Conde, Esther, Hernandez, Susana, Rodriguez Carrillo, Jose Luis, Martinez, Rebeca, Alonso, Marta, Curto, Daniel, Jimenez, Beatriz, Caminoa, Alejandra, Benito, Amparo, Garrido, Pilar||, Clavé, Sergi||, Arriola, Edurne||, Esteban-Rodriguez, Isabel, De Castro, Javier||, Sansano, Irene||, Felip, Enriqueta||, Rojo, Federico||, Dómine Gómez, Manuel||, Abdulkader, Ihab, Garcia-Gonzalez, Jorge, Teixidó, Cristina||, Reguart, Noemi||, Compañ, Desamparados, Insa, Amelia||, Mancheño, Nuria, Palanca, Sarai, Juan-Vidal, Oscar, Baixeras, Nuria||, Nadal, Ernest||, Cebollero, Maria, Calles, Antonio, Martin, Paloma, Salas, Clara, Provencio, Mariano, Aranda, Ignacio, Massuti, Bartomeu||, López Vilaró, Laura||, Majem, Margarita||, Paz-Ares, Luis||, Lopez-Rios, Fernando   +39 more
openaire   +1 more source

Rapid response to selpercatinib in RET fusion positive pancreatic neuroendocrine carcinoma confirmed by smartwatch. [PDF]

NPJ Precis Oncol
Deschler-Baier B, Krebs M, Kroiss M, Chatterjee M, Gundel D, Kestler C, Kerscher A, Kunzmann V, Appenzeller S, Maurus K, Rosenwald A, Bargou R, Gerhard-Hartmann E, Venkataramani V.   +13 more
europepmc   +1 more source

Exposure‐Response Relationships for Pralsetinib in Patients with RET‐Altered Thyroid Cancer or RET Fusion‐Positive Nonsmall Cell Lung Cancer [PDF]

Nastya Kassir, David McDougall, Denison Kuruvilla, Sean Kim, Shaun S. Kumar, Ahmadur Rahman, Thorsten Ruf, Sravanthi Cheeti, Wendy Ankrom   +8 more
openalex   +1 more source

Case Report: CD34-Negative, S100-Positive Spindle Cell Tumor With a <i>MYH10-RET</i> Fusion. [PDF]

Case Rep Pathol
Wang Y, Li X, Yao C, Zhou Z, Liu W, Ni H.   +5 more
europepmc   +1 more source

PP01.93 RET fusion as a treatable resistance mechanism in EGFR mutation lung cancer - A case report [PDF]

Vivek Athipatla, Ashley Hall, Marta Dahiya, Kalyani Narra   +3 more
openalex   +1 more source

A Locally Advanced NSCLC Patient Harboring a Rare KIF13A-RET Fusion Benefited from Pralsetinib: A Case Report. [PDF]

Curr Oncol
Chang Z, Zhu T, Jiang H, Ou W, Wang S.
europepmc   +1 more source

61P Treatment patterns and outcomes of patients with RET fusion-positive non-small cell lung cancer (NSCLC) treated with selpercatinib in Europe: Final results from the SPRINT-RET study [PDF]

M.J. Hochmair, G. Lo Russo, L.A. Leon Mateos, S. Popat, S. Hashemi, D.T. Rieke, T. Puri, M. Khanal, Jennifer R. Kiesel, A.S. Afonso, Montse Pedrós, Daniel Cuadras, G. Segall   +12 more
openalex   +1 more source

Lazarus Response to Selpercatinib for Bleeding Colic Metastasis in a Patient With RET Fusion-Positive Pulmonary Sarcomatoid Carcinoma: A Case Report. [PDF]

Cureus
Monaca F, Vita E, Lococo F, Tortora G, Bria E.   +4 more
europepmc   +1 more source